Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafolecimab in AMI patients undergoing PCI
NCT06683131Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Nov 2025
- Primary completion
- Nov 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tafolecimab in acute myocardial infarction (AMI) (2 arms), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: Rate of major adverse cardiovascular events at 1 year. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
tafolecimab
03
Conditions
acute myocardial infarction (AMI)
Beyond the preview
Go deeper on NCT06683131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06683131.